Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating preferences for online psychological interventions to decrease cannabis use in young adults with psychosis: An observational study.
Tatar O, Abdel-Baki A, Dyachenko A, Bakouni H, Bahremand A, Tibbo PG, Crockford D, Roy MA, Copeland J, Fischer B, Lecomte T, Côté J, Ouellet-Plamondon C, L'Heureux S, Villeneuve M, Jutras-Aswad D. Tatar O, et al. Among authors: bakouni h. Psychiatry Res. 2023 Aug;326:115276. doi: 10.1016/j.psychres.2023.115276. Epub 2023 May 30. Psychiatry Res. 2023. PMID: 37301021 Free article.
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Elkrief L, et al. Among authors: bakouni h. J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30. J Subst Use Addict Treat. 2023. PMID: 37003540 Free article. Clinical Trial.
Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H, McAnulty C, Tatar O, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bakouni H, et al. Am J Addict. 2023 Sep;32(5):469-478. doi: 10.1111/ajad.13439. Epub 2023 Jun 12. Am J Addict. 2023. PMID: 37308805 Clinical Trial.
Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, Bach P, Ezard N, Le Foll B, Schütz CG, Siefried KJ, Tardelli VS, Ziegler D, Jutras-Aswad D. Sharafi H, et al. Among authors: bakouni h. Addiction. 2024 Feb;119(2):211-224. doi: 10.1111/add.16347. Epub 2023 Oct 25. Addiction. 2024. PMID: 37880829 Review.
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H, Sharafi H, Drouin S, Fortin R, Marsan S, Brissette S, Socias ME, Le Foll B, Lim R, Jutras-Aswad D. Bakouni H, et al. Can J Psychiatry. 2024 Apr;69(4):252-263. doi: 10.1177/07067437231210796. Epub 2023 Oct 30. Can J Psychiatry. 2024. PMID: 37899716 Clinical Trial.
Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, Ezard N, Siefried K, Jutras-Aswad D. Bakouni H, et al. Drug Alcohol Depend. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4. Drug Alcohol Depend. 2023. PMID: 37979478 Review.
13 results